Rotavirus infection and prevention

Current Opinion in Pediatrics

Volumn 9, Issue 1, 1997, Pages 19-23

  Barnes, Graeme L ^a   Bishop, Ruth F ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN ANTIBODY; ROTAVIRUS VACCINE;

BREAST FEEDING; CLINICAL FEATURE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNITY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; ROTAVIRUS; VACCINATION; VIRUS INFECTION;

EID: 0030888860     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199702000-00006     Document Type: Review

References (52)

1. Midthun K, Kapikian AZ: Rotavirus vaccines: an overview. Clin Microbiol Rev 1996, 9:423-434.
2. Bishop RF: Natural history of human rotavirus infection. Arch Virol 1997, in press.
3. Kapikian AZ, Chanock RM: Rotaviruses. In Virology, edn 3. Edited by Fields BN, Knife DM. Philadelphia: Lippincott-Raven; 1996:1657-1708.
4. Estes MK: Rotaviruses and their replication. In Virology, edn 3. Edited by Fields BN, Knife DM. Philadelphia: Lippincott-Raven; 1996:1625-1655.
5. Yoshida A, Kawamitu T, Tanaka R, et al.: Rotavirus encephalitis: detection of the virus genomic RNA in the cerebrospinal fluid of a child. Pediatr Infect Dis J 1995, 14:914-916.
6. Pang X-L, Joensuu J, Vesikari T: Detection of rotavirus RNA in cerebrospinal fluid in a case of rotavirus gastroenteritis with febrile seizures. Pediatr Infect Dis J 1996, 15:534-545.
7. Komon H, Wada M, Eto M, et al.: Benign convulsions with mild gastroenteritis: a report of 10 recent cases detailing varieties. Brain Dev 1995, 17:334-337.
8. Makino M, Tanabe Y, Shinozaki K, et al.: Haemorrhagic shock and encephalopathy associated with rotavirus infection. Acta Paediatr Jpn 1996, 85:632-634.
9. Ho L, Bradford BJ: Hypernatremic dehydration and rotavirus enteritis. Clin Pediatr 1995, 34:440-441.
10. De La Rubia L, Herrera MI, Cebrero M, De Jong JC: Acute pancreatitis associated with rotavirus infection. Pancreas 1996, 12:98-99.
11. Limbos MAP, Liberman JM: Disseminated intravascular coagulation associated with rotavirus gastroenteritis: report of two cases. Clin Infect Dis 1996, 22:834-836.
12. Riedel F, Kroener T, Stein K, et al.: Rotavirus infection and bradycardia-apnoea episodes in the neonate. Eur J Pediatr 1996, 155:36-40.
13. Ferson MJ: Hospitalisations for rotavirus gastroenteritis among children under five years of age in New South Wales. Med J Aust 1996, 164:273-276. Patterns of hospital admissions for acute gastroenteritis in Australian children younger than 5 years of age with laboratory reports of rotavirus infection.
14. Bos P, Kirsten M, Cronje RE, Steele AD: Monitoring of rotavirus infection in a paediatric hospital by RNA electrophoresis. S Afr Med J 1995, 85:887-891.
15. Bennet R, Hedlund KO, Ehrnst A, Eriksson M: Nosocomial gastroenteritis in two infant wards over 26 months. Acta Paediatr Scand 1995, 84:667-671.
16. Akhter J, Al-Hajjar S, Myint S, Hussain Qadri SM: Viral contamination of environmental surfaces on a general paediatric ward and playroom in a major referral centre in Riyadh. Eur J Epidemiol 1995, 11:587-590. Rotavirus contamination of environmental surfaces in a hospital.
17. Ojeh CK, Cusack TM, Yolken RH: Evaluation of the effects of disinfectants on rotavirus RNA and infectivity by the polymerase chain reaction and cell-culture methods. Mol Cell Probes 1995, 9:341-346. Evaluation of seven different methods of disinfection or inactivation of rotavirus.
18. Gajardo R, Bouchriti N, Pinto RM, Bosch A: Qenotyping of rotaviruses isolated from sewage. Appl Environ Microbiol 1995, 61:3460-3462.
19. Nirdnoy W, Sethabutr O, Sakulkaipeara T, et al.: Typing of human group A rotavirus with alkaline phosphatase-labeled oligonucleotide probes or a monoclonal enzyme immunoassay in unfrozen stools of children with diarrhea in Bangkok. J Med Virol 1995, 45:117-120.
20. Steele AO, Van Niekerk MC, Mphahlele MJ: Geographic distribution of human rotavirus VP4 genotypes and VP7 serotypes in five South African regions. J Clin Microbiol 1995, 33:1516-1519.
21. Silberstein I, Shulman LM, Mendelson E, Shif I: Distribution of both rotavirus VP4 genotypes and VP7 serotypes among hospitalized and nonhospitalized Israeli children. J Clin Microbiol 1995, 33:1421-1422.
22. Maunula L, Bonsdorff C-HV: Rotavirus serotypes and electropherotypes in Finland from 1986 to 1990. Arch Virol 1995, 140:877-890.
23. Szucs G, Matson DO, Uj M: Group A rotavirus G type prevalence in two regions of Hungary. Arch Virol 1995, 140:1693-1703.
24. Ramachandran M, Das BK, Vij A: Unusual diversity of human rotavirus G and P genotypes in India. J Clin Microbiol 1996, 34:436-439. Illustrative of the complexity of rotavirus serotypes causing disease in children in a developing country.
25. Dunn SJ, Fiore L, Werner RL: Immunogenicity, antigenicity, and protection efficacy of baculovirus expressed VP4 trypsin cleavage products, VP5(1)* and VP8* from rhesus rotavirus. Arch Virol 1995, 140:1969-1978.
26. Contreras JF, Menchaca GE, Padilla-Noriega L, et al.: Heterogeneity of VP4 neutralization epitopes among serotype P1A human rotavirus strains. Clin Diagn Lab Immunol 1995, 2:506-508.
27. Husain M, Seth P, Dar L, Broor S: Classification of rotavirus into G and P types with specimens from children with acute diarrhea in New Delhi, India. J Clin Microbiol 1996, 34:1592-1594.
28. Mphahlele MJ, Steele AD: Relative frequency of human rotavirus VP4 (P) genotypes recovered over a ten-year period from South African children with diarrhea. J Med Virol 1995, 47:1-5.
29. Jiang B, Dennehy PH, Spangenberger S, et al.: First detection of group C rotavirus in fecal specimens of children with diarrhea in the United States. J Infect Dis 1995, 172:45-50.
30. Riepenhoff-Talty M, Gouvea V, Evans MJ: Detection of Group C rotavirus in infants with extrahepatic biliary atresia. J Infect Dis 1996, 174:8-15. Presents evidence of a possible relationship between group C rotavirus and extrahepatic biliary atresia.
31. Rennels MB, Glass RI, Dennehy PH: Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines-report of the National Multicenter Trial: United States Rotavirus Vaccine Group. Pediatrics 1996, 97:7-13.
32. Berstein DI, Glass RI, Rodgers G: Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children: US Rotavirus Vaccine Efficacy Group. JAMA 1995, 273:1191-1196.
33. Treanor JJ, Clark HF, Pichichero M, et al.: Evaluation of the protective efficacy of a serotype 1 bovine-human rotavirus reassortant vaccine in Infants. Pediatr Infect Dis J 1995, 14:301-307.
34. Ward RL, Bernstein DI: Lack of correlation between serum rotavirus antibody titers and protection following vaccination with reassortant RRV vaccines: US Rotavirus Vaccine Efficacy Group. Vaccine 1995, 13:1226-1232.
35. Isolauri E, Joensuu J, Suomalainen H: Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine 1995, 13:310-312.
36. Smith JC, Haddix AC, Teutsch SM, Glass RI: Cost-effectiveness analysis of a rotavirus immunization program for the United States. Pediatrics 1995, 96:609-615. Presents evidence that economic and disease-reduction benefits would be realized in the United States from the use of a rotavirus vaccine that is partially protective (vaccine efficacy rate of 50%).
37. Lanata CF, Black RE, Flores J, et al.: Immunogenicity, safety and protective efficacy of one dose of rhesus rotavirus vaccine and serotype 1 and 2 human-rhesus rotavirus reassortants in children from Lima, Peru. Vaccine 1996, 14:237-243.
38. Rennels MB, Wasserman SS, Glass RI, Keane VA: Comparison of immunogenicity and efficacy of rhesus rotavirus reassortant vaccines in breastfed and nonbreastfed children: US Rotavirus Vaccine Efficacy Group. Pediatrics 1995, 96:1132-1136. Evidence that an oral rotavirus vaccine might be equally immunogenic and protective in breastfed and nonbreastfed children in the United States.
39. Rennels MB, Ward RL, Mack ME, Zito ET: Concurrent oral poliovirus and rhesus-human reassortant rotavirus vaccination: effects on immune responses to both vaccines and on efficacy of rotavirus vaccines: The US Rotavirus Vaccine Efficacy Group. J Infect Dis 1996, 173:306-313. Evidence that it may be possible to combine oral administration of oral poliovirus vaccine and rhesus-human rotavirus vaccines in the United States.
40. Shaw RD, Hempson SJ, Mackow ER: Rotavirus diarrhea is caused by nonreplicating viral particles. J Virol 1995, 69:5946-5950.
41. Ball JM, Tian P, Zeng CO-Y: Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein. Science 1996, 272:101-104. This is an intriguing paper that may be the first identification of a viral enterotoxin.
42. Unicomb LE, Faruque SM, Malek MA, et al.: Demonstration of a lack of synergistic effect of rotavirus with other diarrheal pathogens on severity of diarrhea in children. J Clin Microbiol 1996, 34:1340-1342.
43. Molyneaux PJ: Human immunity to rotavirus (review). J Med Microbiol 1995, 43:397-404. A comprehensive review of current understanding of active immunity to rotavirus-mucosal, systemic local, and cell-mediated immunity. Also discussion about passive immunity via breast milk or oral immunoglobulin administration.
44. Yuan L, Ward LA, Rosen BI, et al.: Systemic and intestinal antibody-secreting cell responses and correlates of protective immunity to human rotavirus in a gnotobiotic pig model of disease. J Virol 1996, 70:3075-3083.
45. Franco MA, Greenberg HB: Role of B cells and cytotoxic T lymphocytes in clearance of and immunity to rotavirus infection in mice. J Virol 1995, 69:7800-7806.
46. Burns JW, Siadat-Pajouh M, Krishnaney AA, Greenberg HB: Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 1996, 272:104-107. This report supports the concept that intracellular viral inactivation by secretory IgA during transcytosis may be a host defense mechanism.
47. Bogstedt AK, Johansen K, Hatta H: Passive immunity against diarrhea. Acta Paediatr 1996, 85:125-128. Passive immunity using oral administration of antibodies is reviewed. Prophylactic use has been previously reported. This report focuses on therapeutic use.
48. Pickering LK, Morrow AL, Herrera I: Effect of maternal rotavirus immunization on milk and serum antibody titers. J Infect Dis 1995, 172:723-728.
49. Mitra AK, Mahalanabis D, Ashraf H: Hyperimmune cow colostrum reduces diarrhea due to rotavirus: a double-blind, controlled clinical trial. Acta Paediatr 1995, 84:996-1001.
50. Fitts SW, Green M, Reyes J, et al.: Clinical features of nosocomial rotavirus infection in pediatric liver transplant recipients. Clin Transpl 1995, 9:201-204.
51. Majamaa H, Isolauri E, Saxelin M, Vesikari T: Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr 1995, 20:333-338.
52. Glass RI, Gentsch JR, Ivanoff B: New lessons for rotavirus vaccines. Science 1996, 272:46-48. A perceptive review of current questions related to rotavirus vaccine trials and questions relating to pathogenesis and immune responses that may initiate new approaches to vaccine development.